Pharmaceutical Technology· GlobalData Healthcare·· 8 小时前AI 评分12
ESMO26：MOIO 试验中标准给药方案优于 12 周间隔检查点抑制剂
ESMO26: Standard dosing prevails over 12-week checkpoint inhibitors in MOIO trial
AI 导读
ESMO26 公布的 MOIO 试验显示，标准给药方案的检查点抑制剂疗效优于 12 周间隔给药。该结果支持在免疫检查点抑制剂治疗中维持标准给药间隔，而非延长至 12 周。
正文 · 原文
Unlock FREE Access to Premium Content
Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends.
With a free Pharmaceutical Technology profile, you can:
- Access exclusive analyst commentary and expert insights
- View premium forecasts and data-driven pharmaceutical industry insights
- Stay up to date with pharma news, manufacturing innovation, and regulatory developments
- Receive alerts when new premium content is published
Unlock free access
Already have an account? Login here
Powered by
来源：Pharmaceutical Technology · pharmaceutical-technology.com